FDA vet — and Woodcock nemesis — John Jenkins is stepping over to a new role as a board member at Corbus Pharma
After making headlines for his part in the FDA’s painful rupture over Sarepta’s Duchenne approval, news of John Jenkins has been rather slow. But now …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
